• María Alejandra Picconi.
• Servicio Virus Oncogénicos, Laboratorio Nacional y Regional de Referencia de Virus Papiloma Humano para las Américas (OPS/OMS), Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos Malbrán, Buenos Aires. E-mail: mapicconi@gmail.com.
• Medicina (B Aires). 2013 Jan 1; 73 (6): 585596585-96.

AbstractCervical cancer (CC), which is strongly associated to high-risk human papillomavirus (hr-HPV) infection, continues being a significant health problem in Latin America. The use of conventional cytology to detect precancerous cervical lesions has had no major impact on reducing CC incidence and mortality rates, which are still high in the region. New screening tools to detect precancerous lesions became available, which provide great opportunities for CC prevention, as do highly efficacious HPV vaccines able to prevent nearly all lesions associated with HPV-16 and -18 when applied before viral exposure. Currently, hr-HPV testing represents an invaluable component of clinical guidelines for screening, management and treatment of CC and their precursor lesions. Many testing strategies have been developed that can detect a broad spectrum of hr-HPV types in a single assay; however, only a small subset of them has documented clinical performance for any of the standard HPV testing indications. HPV tests that have not been validated and lack proof of reliability, reproducibility and accuracy should not be used in clinical management. Once incorporated into the lab, it is essential to submit the whole procedure of HPV testing to continuous and rigorous quality assurance to avoid sub-optimal, potentially harmful practices. Recent progress and current status of these methods are discussed in this article.

31 keywords...

hide…